ClinicalTrials.gg
Not yet recruitingNCT07951177PED-MRUpdated Nov 20, 2026

Pediatric Eustachian Tube Dilatation in the Management of Mesotympanic Retraction With Effusion.

An interventional study of Eustachian tube dilation added to standard treatment and Standard treatment in Otitis Media, Eustachian Tube Disorder and Chronic Otitis Infections in pédiatric Patients, sponsored by University Hospital, Montpellier. Not yet recruiting at 7 sites in France. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Study summary

The goal of this clinical investigation is to evaluate the effectiveness of ETD + standard treatment versus standard treatment only, on the improvement of the tympanic membrane retraction, up to 18 months after intervention in children aged ]8-17[ with posterior mesotympanic retraction and middle ear effusion.

02

Conditions studied

  • Otitis Media
  • Eustachian Tube Disorder
  • Chronic Otitis Infections in pédiatric Patients
  • Retraction Pocket of the Tympanic Membrane

Browse trials for

03

In context

Otitis Media

244 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

This study's planned enrollment of 272 is above the median of 165 across 174 interventional studies indexed under Otitis Media.

Browse Otitis Media studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged strictly between 8 and 17 years of age
  • Presenting a posterior mesotympanic retraction (grade II or III without adherence to the promontory from Sade's grade) with effusion

Exclusion criteria

Exclusion Criteria:

  • Weight strictly less than 20kg
  • Down syndrome
  • Craniosynostosis and other head and neck malformations
  • History of skull base surgery
  • History of skull fracture
  • Failure to obtain consent
  • Non-affiliation to a social security scheme
  • Persons placed under legal protection
  • Person participating in another research including a period of exclusion still in progress
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Eustachian tube dilation added to standard treatment

    Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present. ETD involves using a transnasal balloon catheter, during general anesthesia, by the surgeon in charge of the patient. The device will be an Acclarent Aera 6x16 mm balloon, with a pressure set at 12 atm for 2 minutes in the eustachian tube. The manufacturer of the ETD device will organize a training session with hands-on on simulator, for all the principal investigators prior to the start of the study, to ensure homogenous intervention.

    Device: Eustachian tube dilation added to standard treatment

  • Active comparator
    Standard treatment

    Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present, during general anesthesia, by the surgeon in charge of the patient. Tube placement will be in the anterior or inferior part of the tympanic membrane. Different design and brand of tympanostomy tube exist and are used in the different centers, leading to putative slightly different outcomes in term of adverse events related to the tympanostomy tube and duration. To decrease the cohort's heterogeneity, we propose to utilize the same tympanostomy tube for all the patients included in the study (Shepard's tympanostomy tube).

    Device: Standard treatment

Interventions

  • DeviceEustachian tube dilation added to standard treatment

    Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical, coupled with the Acclarent Aera™ Eustachian Tube Balloon Dilation System.

  • DeviceStandard treatment

    Medical device: Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical.

06

What researchers measure

Primary outcomes

  1. Tympanic membrane retraction

    The assessment of tympanic membrane retraction is treated as a survival variable. Tympanic membrane retraction will be blindly assessed by an adjudication committee, through recorded otoendoscopy, based on the Sade's classification (in grade 0, I, II, III, IV, or V). The delay will be calculated as the time from intervention to improvement in tympanic membrane retraction (event), to loss of follow up (censoring), or to the study endpoint (censoring).

    Time frame: Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.

Secondary outcomes

  1. Mesotympanic retractation

    Mesotympanic retractation according to Sade's classification

    Time frame: 6, 12 and 18 months

  2. Audiometry thresholds

    Mean of the air-bone gap at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz

    Time frame: 6, 12 and 18 months

  3. Tympanometry profile

    Tympanometry profile (A, B or C)

    Time frame: 6, 12 and 18 months

  4. The quality of life

    Quality of Life measured through the OM-6 questionnaires

    Time frame: 6, 12 and 18 months

  5. The quality of life

    Quality of Life measured through the PedsQL™ 4.0 questionnaires

    Time frame: 6, 12 and 18 months

  6. Adverse events in both arms

    Occurrence of adverse events and serious events during the first week, coded according to MedDRA.

    Time frame: during the first week

07

Study locations

7 sites
  • Richard NICOLLAS
    Marseille, APHM 13005, France
  • François SIMON
    Paris, APHP Hôpital Necker 75006, France
  • Thiery VAN DEN ABBEELE
    Paris, APHP Hôpital Robert Debre 75019, France
    • Thiery VAN DEN ABBEELE, PhD · Contactthierry.van-den-abbeele@aphp.fr · 0140032179
    • Natacha TEISSIER, PhD · Sub investigator
    • Charlotte BENOIT, Dr · Sub investigator
    • Emilie BOIS, Dr · Sub investigator
  • Sonia AYARI
    Lyon, HCL Hôptial Femme Mere Enfant 69677, France
  • Marie-Noël CALMELS
    Toulouse, Hôpital Purpan 40031, France
    • Marie-Noël CALMES, PhD · Contactcalmels.mn@chu-toulouse.fr · 0561779009
    • Blandine BALADI · Sub investigator
    • Yohan GALLOIS · Sub investigator
  • Philippine TOULEMONDE
    Lille, Hôpital Salengro 5900, France
  • Fabian BLANC
    Montpellier, 34000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Jun 2030, 39 months later.

Of 36 non-industry interventional studies with no phase under Otitis Media, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's planned 39 months is close to that.

Counting every sponsor, half of 45 studies reached it within 38 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Jun 1, 2030
CompletionEst.
Dec 1, 2032
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951177
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Jun 1, 2030 (estimated)
Completion
Dec 1, 2032 (estimated)
Last update
Nov 20, 2026

Study contacts

Fabian BLANC, Dr
Contact
fabian-blanc@chu-montpellier.fr
0668248182 ext. +33
Fabian BLANC, Dr
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion